# Clinical Cases: Menopause

## Case 1: Menopausal Vasomotor Symptoms and Hormone Therapy

### Clinical Image
![Menopause](case_01_image.jpg)
*Source: [Wikipedia - Menopause](https://en.wikipedia.org/wiki/Menopause) - CC BY-SA 4.0*

### Case Presentation
A 52-year-old woman presents with severe hot flashes that have significantly impacted her quality of life for the past year. She reports 10-12 hot flashes daily, each lasting 2-4 minutes, accompanied by profuse sweating and palpitations. Night sweats wake her 3-4 times nightly, causing chronic sleep deprivation. Her last menstrual period was 14 months ago. She has tried lifestyle modifications including keeping the room cool, wearing layers, avoiding triggers (alcohol, spicy foods), and taking black cohosh supplements without improvement. Her medical history is unremarkable with no history of VTE, cardiovascular disease, or breast cancer. Family history is negative for breast cancer. BMI is 24, and she does not smoke. Physical examination is normal. Based on her age and 12+ months of amenorrhea, she is diagnosed with menopause; laboratory testing is not required. Given her severe symptoms affecting quality of life, no contraindications to hormone therapy, and timing within 10 years of menopause onset (favorable per the "timing hypothesis"), she is started on transdermal estradiol 0.05 mg patch twice weekly plus oral micronized progesterone 200 mg for 12 days per month for endometrial protection. At 8-week follow-up, her hot flashes have decreased by 80%, sleep has improved dramatically, and she reports significantly better quality of life.

### Key Learning Points
- Vasomotor symptoms (hot flashes and night sweats) affect 75-80% of women during the menopausal transition and persist for a median of 7-10 years
- Hormone therapy is the most effective treatment for vasomotor symptoms, reducing hot flash frequency by approximately 75%
- The "timing hypothesis" supports initiating HT within 10 years of menopause or before age 60, when cardiovascular benefits may outweigh risks
- Women with an intact uterus require progestogen (progesterone or progestin) to prevent endometrial hyperplasia from unopposed estrogen; micronized progesterone has favorable lipid and sleep-promoting effects

---

## Case 2: Genitourinary Syndrome of Menopause

### Clinical Image
![Vaginal Atrophy](case_02_image.jpg)
*Source: [Wikipedia - Atrophic vaginitis](https://en.wikipedia.org/wiki/Atrophic_vaginitis) - CC BY-SA 3.0*

### Case Presentation
A 62-year-old woman presents with vaginal dryness, painful intercourse, and recurrent urinary tract infections. She went through menopause at age 51 and had mild hot flashes that resolved within a few years without treatment. Over the past 3 years, she has developed progressive vaginal dryness causing significant dyspareunia. She and her husband have essentially stopped having intercourse due to her discomfort. She has also had 4 UTIs in the past year despite adequate hydration. Physical examination reveals pale, thin vaginal epithelium with loss of rugae, petechiae, and a vaginal pH of 6.0 (normal premenopausal pH is 3.5-4.5). The urethral meatus appears prominent. She has no history of breast cancer and her mammograms have been normal. She declines systemic hormone therapy as she has no vasomotor symptoms. The diagnosis is genitourinary syndrome of menopause (GSM). She is counseled that unlike hot flashes, GSM is progressive and will not resolve without treatment. She is started on vaginal estrogen cream (conjugated estrogens 0.5 g intravaginally twice weekly). At 12-week follow-up, she reports marked improvement in vaginal comfort and has resumed sexual activity. The vaginal epithelium appears healthier, and pH has decreased to 4.5. No UTIs have occurred since starting treatment.

### Key Learning Points
- Genitourinary syndrome of menopause (GSM) affects approximately 50% of postmenopausal women and includes vaginal dryness, dyspareunia, urinary urgency/frequency, and recurrent UTIs
- Unlike vasomotor symptoms, GSM is progressive and does not resolve spontaneously; treatment is required to prevent progression
- Low-dose vaginal estrogen is the most effective treatment for GSM with minimal systemic absorption; it is safe even in many women with contraindications to systemic HT
- Alternative treatments include vaginal DHEA (prasterone), the oral SERM ospemifene, and non-hormonal vaginal moisturizers and lubricants

---

## Case 3: Premature Ovarian Insufficiency

### Clinical Image
![Premature Ovarian Insufficiency](case_03_image.jpg)
*Source: [Wikipedia - Premature ovarian failure](https://en.wikipedia.org/wiki/Premature_ovarian_failure) - CC BY-SA 4.0*

### Case Presentation
A 32-year-old woman presents with 8 months of amenorrhea after previously regular menstrual cycles. She also reports hot flashes, vaginal dryness, and difficulty concentrating. She and her husband have been trying to conceive for the past year without success. She has no history of chemotherapy, radiation, or ovarian surgery. There is a family history of a maternal aunt who went through menopause at age 35 and a cousin with intellectual disability. Physical examination reveals no goiter and normal secondary sexual characteristics. Laboratory studies show FSH 65 mIU/mL (elevated), estradiol 18 pg/mL (low), and negative pregnancy test. TSH is normal. A repeat FSH one month later is 58 mIU/mL, confirming the diagnosis of premature ovarian insufficiency (POI). Given the family history suggesting possible fragile X syndrome, FMR1 gene testing is performed and reveals she is a fragile X premutation carrier (75 CGG repeats). Karyotype is 46,XX. She is counseled about the genetic implications for herself (risk of fragile X-associated tremor/ataxia syndrome) and for family members. Regarding fertility, she is counseled that while spontaneous ovulation may occur intermittently in 5-10% of women with POI, her best option for pregnancy is donor egg IVF. She is started on hormone replacement therapy with transdermal estradiol plus cyclic oral progesterone, which she should continue until at least age 51 to prevent osteoporosis, cardiovascular disease, and urogenital atrophy associated with premature estrogen deficiency.

### Key Learning Points
- Premature ovarian insufficiency (POI) is defined as ovarian failure before age 40, affecting approximately 1% of women; diagnosis requires two elevated FSH levels (>25-40 mIU/mL) measured at least one month apart
- All women with POI should be tested for FMR1 gene (fragile X premutation), which causes 2-5% of POI cases and has implications for family members at risk for fragile X syndrome
- Hormone replacement therapy is strongly recommended until the average age of natural menopause (51 years) to prevent long-term consequences of estrogen deficiency including osteoporosis, cardiovascular disease, and cognitive decline
- Unlike natural menopause, HRT in young women with POI represents physiologic replacement rather than pharmacologic therapy, and the risks associated with HT in older women do not apply